TRACE: A Governance Framework for Measuring Explainability Debt in Production AI Systems
Abstract
Production AI systems deployed in high-stakes domains accumulate a governance liability that existing monitoring frameworks fail to detect: the progressive inability to explain individual decisions when regulators, auditors, or affected individuals demand accountability. We introduce TRACE (Transparency, Risk, Accountability, Compliance, and Explainability), a seven-instrument governance framework for measuring, tracking, and remediating Explainability Debt in production AI systems. The foundational instrument, the Explainability Debt Score (EDS), quantifies the proportion of production decisions falling below a governance-defined explainability confidence threshold at any point in time. Complementary instruments include DART (Debt Accumulation Rate Tracker for breach forecasting), SHIV (Scenario Health and Integrity Validator for daily governance), FDE (Feature Drift Evaluator for causal attribution), HVE (Human Validation Engine), AIDE (Audit Intervention Decision Engine), and ZERO (Zero Explainability Risk Optimiser for remediation). Through a twelve-month longitudinal case study of a production fraud detection system processing 50,000 daily financial transactions, achieving 98.46% accuracy and ROC-AUC of 0.9990, we demonstrate that an EDS of 0.23 on audit day was statistically predictable six months in advance using DART trajectory analysis (beta = 0.008/week, R-squared = 0.94, 95% CI: [0.006, 0.010]), and that 78% of Explainability Debt was concentrated in the…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.